ArticleClinical and experimental medicine2025
A bi-specific CAR-T cell therapy targeting CD19 and CD22 in relapsed or refractory B-ALL.
Qiuling Ma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it